Ventripoint Appoints New CFO to Drive Global Expansion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 08 2025
0mins
Source: Globenewswire
- Leadership Strengthening: Ventripoint Diagnostics has appointed David Swetlow as CFO to leverage his 25 years of experience in medical technology management, aiming to drive the global expansion of the VMS+ cardiac imaging platform and enhance the company's competitiveness in international markets.
- Commercial Strategy Update: The new CFO will support the execution of a refreshed commercial strategy focused on market adoption and revenue growth, particularly as nearly 40% of hospitals face negative margins, compelling rapid adoption of AI technologies that generate revenue.
- Technological Collaboration Progress: Ventripoint's collaboration with Providence Health Care Ventures will validate VMS+ at St. Paul's Hospital in Vancouver, with implementation expected in early 2026, aiming to enhance the efficiency of cardiac echocardiography using AI and reduce the demand for cardiac MRI scans.
- Regulatory Compliance Improvement: The company completed a quality audit in September with zero major nonconformities, maintaining FDA clearance and EU certification, indicating the clinical effectiveness of its technology and laying a solid foundation for future commercialization.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IRTC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IRTC
Wall Street analysts forecast IRTC stock price to rise
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 123.750
Low
205.00
Averages
222.00
High
244.00
Current: 123.750
Low
205.00
Averages
222.00
High
244.00
About IRTC
iRhythm Holdings, Inc. is a digital health care company, which creates solutions that detect, predict, and prevent disease. It designs, develops, and commercializes device-based technology to provide ambulatory cardiac monitoring services. It offers three Zio System options: the Zio Monitor System, the Zio XT System, and the Zio AT System. It offers its Zio ambulatory cardiac monitoring services, including long-term continuous monitoring, short-term continuous monitoring, and mobile cardiac telemetry (MCT) monitoring services, using its Zio Systems. The Zio Monitor System is a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor (the Zio Monitor patch) that records the electric signal from the heart continuously for over 14 days and the Zio ECG Utilization Software (ZEUS) System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
iRhythm Holdings Reports Strong Q4 2025 Earnings Growth
- Significant Revenue Growth: iRhythm reported Q4 2025 revenue of $208.9 million, reflecting a 27.1% year-over-year increase, with full-year revenue reaching $747.1 million, a 26.2% growth, underscoring strong performance in cardiology and primary care, thereby solidifying market position.
- Profitability Breakthrough: The company achieved a net income of $5.6 million for the fourth quarter, translating to $0.17 per diluted share, marking the first positive quarterly net income in its history, with adjusted EBITDA at $34.3 million or 16.4% of revenue, indicating a significant improvement in profitability.
- International Market Expansion: iRhythm has commercialized in the U.K., select EU markets, and Japan, achieving its largest quarterly volume ever in the U.K., highlighting rapid growth potential in international markets that will further drive future revenue growth.
- Optimistic Outlook: The company expects 2026 revenue to range between $870 million and $880 million, representing a 16% to 18% year-over-year growth, while adjusted EBITDA margins are projected to expand to 11.5% to 12.5%, reflecting confidence in sustained growth and profitability.
See More
iRhythm Technologies Exceeds 2025 Earnings Expectations
- Significant Revenue Growth: iRhythm Technologies reported a revenue of $747.1 million for 2025, reflecting a 26.2% year-over-year increase primarily driven by heightened demand for Zio services, indicating strong growth potential in the cardiac monitoring market.
- Improved Gross Margin: The gross profit for 2025 was $527.3 million, with a gross margin of 70.6%, up from 68.9% in 2024, showcasing enhancements in scale and operational efficiencies that contributed to lower unit service costs.
- Reduced Net Loss: The net loss for 2025 was $44.6 million, translating to a diluted loss of $1.39 per share, a significant improvement from the net loss of $113.3 million and diluted loss of $3.63 per share in 2024, reflecting progress towards profitability.
- Optimistic 2026 Guidance: iRhythm anticipates revenue between $870 million and $880 million for 2026, with an adjusted EBITDA margin of 11.5% to 12.5%, indicating continued volume-led growth and disciplined investment in innovation and market expansion.
See More
iRhythm Technologies Set to Announce Q4 Earnings
- Earnings Announcement: iRhythm Technologies is set to release its Q4 2023 earnings on February 19th after market close, with consensus EPS estimates at $0.06, reflecting a 250% year-over-year increase, and revenue estimates at $202.61 million, indicating a 23.3% year-over-year growth, showcasing the company's robust growth potential.
- Performance Beat Record: Over the past two years, iRhythm has beaten EPS estimates 50% of the time and has achieved a 100% beat rate on revenue estimates, underscoring the company's strong reputation among market analysts and consistent performance.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen one upward revision and three downward adjustments, while revenue estimates have experienced seven upward revisions and one downward change, reflecting mixed market sentiment regarding the company's future performance, which could impact investor confidence.
- Future Growth Outlook: iRhythm anticipates exceeding its revenue guidance for 2025 and forecasts up to 18% growth in 2026, demonstrating the company's confidence in future market opportunities and a proactive growth strategy.
See More
Investigation into iRhythm Technologies' Corporate Governance Breaches
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of iRhythm Technologies, Inc. breached their fiduciary duties, potentially impacting corporate governance.
- Legal Relief Options: Long-term shareholders of iRhythm stock may seek corporate governance reforms, fund recovery, or court-approved financial awards, aimed at enhancing transparency and accountability within the company.
- Importance of Participation: Shareholder involvement can improve company policies and oversight mechanisms, thereby increasing shareholder value and enhancing the effectiveness and transparency of management.
- Law Firm Background: Halper Sadeh LLC represents investors globally, focusing on securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors.
See More
iRhythm Technologies Executives Accused of Breaching Fiduciary Duties
- Legal Investigation Launched: Kuehn Law, PLLC is investigating whether executives at iRhythm Technologies, Inc. breached their fiduciary duties to shareholders, as a federal securities lawsuit alleges that executives failed to disclose the true purpose of the Zio AT monitor, potentially harming shareholder interests.
- Market Misleading Actions: Insiders repeatedly touted the Zio AT as an innovative product with growth potential, yet failed to clarify that it was intended for high-risk patients, leading investors to misunderstand its premium pricing and artificially inflate the stock price.
- Shareholder Rights Affected: Due to these misleading actions, iRhythm's stock traded at artificially inflated prices during relevant periods, putting shareholders at risk of investment losses, prompting Kuehn Law to urge shareholders to contact them promptly to protect their rights.
- No Legal Fees: Kuehn Law states that all case costs will be covered by the firm, with no fees charged to investors, encouraging shareholders to get involved to ensure the integrity and fairness of the financial markets.
See More
Kuehn Law Investigates iRhythm Executives for Breach of Fiduciary Duties
- Investigation Background: Kuehn Law, PLLC is investigating whether executives at iRhythm Technologies, Inc. breached their fiduciary duties to shareholders, as a federal securities lawsuit alleges insiders failed to disclose the true purpose of the Zio AT monitor, leading to artificially inflated stock prices.
- Product Misrepresentation: Insiders at iRhythm repeatedly touted the Zio AT as an innovative product with significant growth potential, while it was actually a real-time monitor intended for high-risk patients, which investors viewed favorably due to its premium pricing.
- Stock Price Impact: As a result of these misleading statements, iRhythm's stock traded at artificially inflated prices during relevant periods, potentially causing financial losses for investors, prompting shareholders to contact legal counsel promptly to protect their rights.
- Legal Fee Commitment: Kuehn Law commits to covering all case costs and does not charge its investor clients, encouraging shareholders to get involved to uphold the integrity and fairness of financial markets.
See More
iRhythm Holdings Reports Strong Q4 2025 Earnings Growth
- Significant Revenue Growth: iRhythm reported Q4 2025 revenue of $208.9 million, reflecting a 27.1% year-over-year increase, with full-year revenue reaching $747.1 million, a 26.2% growth, underscoring strong performance in cardiology and primary care, thereby solidifying market position.
- Profitability Breakthrough: The company achieved a net income of $5.6 million for the fourth quarter, translating to $0.17 per diluted share, marking the first positive quarterly net income in its history, with adjusted EBITDA at $34.3 million or 16.4% of revenue, indicating a significant improvement in profitability.
- International Market Expansion: iRhythm has commercialized in the U.K., select EU markets, and Japan, achieving its largest quarterly volume ever in the U.K., highlighting rapid growth potential in international markets that will further drive future revenue growth.
- Optimistic Outlook: The company expects 2026 revenue to range between $870 million and $880 million, representing a 16% to 18% year-over-year growth, while adjusted EBITDA margins are projected to expand to 11.5% to 12.5%, reflecting confidence in sustained growth and profitability.
See More
iRhythm Technologies Exceeds 2025 Earnings Expectations
- Significant Revenue Growth: iRhythm Technologies reported a revenue of $747.1 million for 2025, reflecting a 26.2% year-over-year increase primarily driven by heightened demand for Zio services, indicating strong growth potential in the cardiac monitoring market.
- Improved Gross Margin: The gross profit for 2025 was $527.3 million, with a gross margin of 70.6%, up from 68.9% in 2024, showcasing enhancements in scale and operational efficiencies that contributed to lower unit service costs.
- Reduced Net Loss: The net loss for 2025 was $44.6 million, translating to a diluted loss of $1.39 per share, a significant improvement from the net loss of $113.3 million and diluted loss of $3.63 per share in 2024, reflecting progress towards profitability.
- Optimistic 2026 Guidance: iRhythm anticipates revenue between $870 million and $880 million for 2026, with an adjusted EBITDA margin of 11.5% to 12.5%, indicating continued volume-led growth and disciplined investment in innovation and market expansion.
See More
iRhythm Technologies Set to Announce Q4 Earnings
- Earnings Announcement: iRhythm Technologies is set to release its Q4 2023 earnings on February 19th after market close, with consensus EPS estimates at $0.06, reflecting a 250% year-over-year increase, and revenue estimates at $202.61 million, indicating a 23.3% year-over-year growth, showcasing the company's robust growth potential.
- Performance Beat Record: Over the past two years, iRhythm has beaten EPS estimates 50% of the time and has achieved a 100% beat rate on revenue estimates, underscoring the company's strong reputation among market analysts and consistent performance.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen one upward revision and three downward adjustments, while revenue estimates have experienced seven upward revisions and one downward change, reflecting mixed market sentiment regarding the company's future performance, which could impact investor confidence.
- Future Growth Outlook: iRhythm anticipates exceeding its revenue guidance for 2025 and forecasts up to 18% growth in 2026, demonstrating the company's confidence in future market opportunities and a proactive growth strategy.
See More
Investigation into iRhythm Technologies' Corporate Governance Breaches
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of iRhythm Technologies, Inc. breached their fiduciary duties, potentially impacting corporate governance.
- Legal Relief Options: Long-term shareholders of iRhythm stock may seek corporate governance reforms, fund recovery, or court-approved financial awards, aimed at enhancing transparency and accountability within the company.
- Importance of Participation: Shareholder involvement can improve company policies and oversight mechanisms, thereby increasing shareholder value and enhancing the effectiveness and transparency of management.
- Law Firm Background: Halper Sadeh LLC represents investors globally, focusing on securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors.
See More
iRhythm Technologies Executives Accused of Breaching Fiduciary Duties
- Legal Investigation Launched: Kuehn Law, PLLC is investigating whether executives at iRhythm Technologies, Inc. breached their fiduciary duties to shareholders, as a federal securities lawsuit alleges that executives failed to disclose the true purpose of the Zio AT monitor, potentially harming shareholder interests.
- Market Misleading Actions: Insiders repeatedly touted the Zio AT as an innovative product with growth potential, yet failed to clarify that it was intended for high-risk patients, leading investors to misunderstand its premium pricing and artificially inflate the stock price.
- Shareholder Rights Affected: Due to these misleading actions, iRhythm's stock traded at artificially inflated prices during relevant periods, putting shareholders at risk of investment losses, prompting Kuehn Law to urge shareholders to contact them promptly to protect their rights.
- No Legal Fees: Kuehn Law states that all case costs will be covered by the firm, with no fees charged to investors, encouraging shareholders to get involved to ensure the integrity and fairness of the financial markets.
See More
Kuehn Law Investigates iRhythm Executives for Breach of Fiduciary Duties
- Investigation Background: Kuehn Law, PLLC is investigating whether executives at iRhythm Technologies, Inc. breached their fiduciary duties to shareholders, as a federal securities lawsuit alleges insiders failed to disclose the true purpose of the Zio AT monitor, leading to artificially inflated stock prices.
- Product Misrepresentation: Insiders at iRhythm repeatedly touted the Zio AT as an innovative product with significant growth potential, while it was actually a real-time monitor intended for high-risk patients, which investors viewed favorably due to its premium pricing.
- Stock Price Impact: As a result of these misleading statements, iRhythm's stock traded at artificially inflated prices during relevant periods, potentially causing financial losses for investors, prompting shareholders to contact legal counsel promptly to protect their rights.
- Legal Fee Commitment: Kuehn Law commits to covering all case costs and does not charge its investor clients, encouraging shareholders to get involved to uphold the integrity and fairness of financial markets.
See More
